RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer

Abstract

Keywords

Cost-utility analysis locally advanced breast cancer trastuzumab docetaxel

Get full access to this article

View all access options for this article.

References

World cancer research foundation, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics (accessed May 2017).

Brewster

Hortobagyi

Broglio

et al.

Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008; 100: 1179–1183.

SEER Cancer Statistics Review, 1975–2014, http://seer.cancer.gov/csr/1975_2014 (accessed May 2017).

National Comprehensive Cancer Network. NCCN Practice Guidelines, http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf (accessed 1 May 2017).

Kataja

Castiglione

. ESMO Guidelines Working Group. Locally, recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii11–vii19.

Moreno-Aspitia

Perez

. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009; 84: 533–545.

Murray

Evans

Acharya

et al.

Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000; 9: 235–251.

Statistics times: International Monetary Fund World Economic Outlook (April 2015), http://statisticstimes.com/economy/projected-world-gdp-capitaranking.php (accessed 24 May 2017).

Directorate-General of Budget, Accounting and Statistics Ministry of Foreign Affairs, Republic of China (Taiwan), http://taiwantoday.tw/ct.asp?xItem=239566&ctNode=435 (accessed 24 May 2017).

10.

Diaby

Ali

Adunlin

et al.

Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin 2016; 32: 991–996.

11.

Petrou

Talias

. Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 131–138.

12.

Purmonen

Martikainen

Soini

et al.

Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther 2008; 30: 382–392.

13.

Hedden

O'Reilly

Lohrisch

et al.

Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist 2012; 17: 164–171.

14.

Durkee

Qian

Pollom

et al.

Cost-effectiveness of Pertuzumab in human epidermal growth factor receptor 2-positivemetastatic breast cancer. J Clin Oncol 2016; 34: 902–909.

15.

Drummond

Sculpher

Torrance

. Methods for the economic evaluation of health care programs, Oxford, UK: Oxford University Press, 2005.

16.

Net benefits calculations, TreeAge Pro 2015 User’s Manual. Chapter 32, pp426. TreeAge Software, Inc, 2015.

17.

Dendukuri

Khetani

McIsaac

et al.

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007; 176: 1429–1434.

18.

Andrade

Mosegui

Miranda

et al.

Trastuumab in metastatic breast cancer: systematic review of cost-effectiveness analysis. Int Pharm Pharmaceut Sci 2015; 7: 47–56.

19.

Perez-Ellis

Goncalves

Jacquemier

et al.

Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer. Am J Clin Oncol 2009; 32: 492–498.

20.

Poncet

Bachelot

Colin

et al.

Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008; 31: 363–368.

21.

Norum

Risberg

Olsen

. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909–914.

22.

Neumann

Weinstein

. Legislating against use of cost-effectiveness information. N Engl J Med 2010; 363: 1495–1497.

RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data

Abstract

Keywords

Get full access to this article

References